Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.44 |
| ▸ | NPY1R | P25929 | 6/20 | 0.44 |
| ▸ | NPY2R | P49146 | 4/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27086265 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL8526711 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL8526706 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL31688043 | 0.96 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL29695594 | 0.95 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL30716491 | 0.92 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL30898573 | 0.92 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL29816322 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RPDCD1LG2 | |
| SCHEMBL29850992 | 0.91 | PDCD1LG2 (0.49) | NPY4RNPY1RNPY2RNPY5RPDCD1LG2 | |
| SCHEMBL30531637 | 0.91 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148664-A1 | LIPID AND COMPOSITION | SOGO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4321524-A1 | LIPID AND COMPOSITION | Sogo Pharmaceutical Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148664-A1 | LIPID AND COMPOSITION | PLIN3, PLIN1, FABP1 | NPY4R 1975/4885NPY1R 1962/4885NPY2R 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.